Nuclear Medicine and Biology
Volume 33, Issue 4 , Pages 505-512 , May 2006

Radionuclide imaging of small-cell lung cancer (SCLC) using 99mTc-labeled neurotensin peptide 8–13

  • Kaijun Zhang

      Affiliations

    • Department of Nuclear Medicine, Union Hospital, Tongji Medical School, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China
    • Department of Radiology, Thomas Jefferson University, Philadelphia, PA 19107, USA
    • Corresponding Author InformationCorresponding author. Department of Radiology, Thomas Jefferson University, Philadelphia, PA 19107, USA. Tel.: +1 215 503 7879.
    • ,
  • Rui An

      Affiliations

    • Department of Nuclear Medicine, Union Hospital, Tongji Medical School, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China
    • ,
  • Zairong Gao

      Affiliations

    • Department of Nuclear Medicine, Union Hospital, Tongji Medical School, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China
    • ,
  • Yongxue Zhang

      Affiliations

    • Department of Nuclear Medicine, Union Hospital, Tongji Medical School, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China
    • ,
  • Mohan R. Aruva

      Affiliations

    • Department of Radiology, Thomas Jefferson University, Philadelphia, PA 19107, USA

Received 7 January 2006 ,Revised 23 February 2006 ,Accepted 5 March 2006.

References 

  1. Thakur ML, Aruva MR, Gariepy J, et al. PET imaging of oncogene overexpression using 64Cu-vasoactive intestinal peptide (VIP) analog: comparison with 99mTc-VIP analog. J Nucl Med. 2004;45:1381–1389
  2. Ishizuka J, Townsend CM, Thompson JC, et al. Neurotensin regulates growth of human pancreatic cancer. Ann Surg. 1993;217:439–446
  3. Reubi JC, Waser B, Friess B, et al. Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma. Gut. 1998;42:546–550
  4. Terriere D, Chavatte K, Ceusters M, et al. Neurotensin receptors in human neoplasms: high incidence in Ewing's sarcomas. Int J Cancer. 1999;82:213–218
  5. Vincent J, Mazella J, Kitabgi P. Neurotensin and neurotensin receptors. Trends Pharmacol Sci. 1999;20:302–309
  6. Andre E, Roger A, Lesley T, et al. Organometallic 99mTc-aquaion labels peptide to an unprecedented high specific activity. J Nucl Med. 1999;40:1913–1917
  7. Staley J, Fiskum G, Davis TP, et al. Neurotensin elevates cytosolic calcium in small cell lung cancer cells. Peptides. 1989;10:127–1721
  8. Allen AE, Carney DN, Moody TW, et al. Neurotensin binds with high affinity to small cell lung cancer cells. Peptides. 1988;9:57–61
  9. Ocejo-Garcia M, Ahmed SI, Coulson JM, et al. Use of RT-PCR to detect co-expression of neuropeptides and their receptors in lung cancer. Lung Cancer. 2001;33:1–9
  10. Samreen IA, James T, Judy MC, et al. Studies on the expression of endothelin, its receptor subtypes, and converting enzymes in lung cancer and in human bronchial epithelium. Am J of Res Cell Mol Biol. 2000;20:422–431
  11. Carraway R, Leeman SE. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem. 1973;248:6854–6861
  12. Carraway R, Leeman SE. In:  Walter R, Meienhofer  editor. Peptides: chemistry structure and biology. Ann Arbor: Ann Arbor Science; 1975;p. 679–685
  13. Kyle PK, Thomas AD. Monitoring neurotensin [8–13] degradation in human and rat serum utilizing matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Anal Biochem. 2002;308:34–41
  14. Kitabgi P, De Nadai F, Rovere C, et al. Biosynthesis, maturation, release and degradation of neurotensin and neuromedin N. Ann N Y Acad Sci. 1992;668:30–42
  15. Davis TP, Konings PNM. Peptidases in the CNS: formation of biologically active, receptor-specific peptide fragments. Crit Rev Neurobiol. 1993;7:163–174
  16. Heyl DL, Sefler AM, He JX, et al. Structure–activity and conformational studies of a series of modified C-terminal hexapeptide neurotensin analogues. Int J Pept Protein Res. 1994;44:233–238
  17. Bouwmeester H, Snapper J, Ronken E, et al. Effects of neonatal amygdala lesions on [125I] neurotensin binding in specific brain areas of adult rat. Eur J Neurosci. 2003;17:1319–1322
  18. Achilefu S, Srinivasan A, Schmidt MA, et al. Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors. J Med Chem. 2003;46:3403–3411
  19. Albert R, Schibli R, Abram U, et al. A novel organometallic aqua-complex of technetium for the labeling of biomolecules: synthesis of [99Tcm(H2O)3(CO)3]+ in aqueous solution and its reaction with a bifunctional ligand. J Am Chem Soc. 1998;120:7987–7988
  20. Bergmann R, Scheunemann M, Heichert C, et al. Biodistribution and catabolism of (18)F-labeled neurotensin(8–13) analogs. Nucl Med Biol. 2002;29:61–72
  21. de Visser M, Janssen PJ, Sirnivasan A, et al. Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer. Eur J Nucl Med Mol Imaging. 2003;30:1134–1139
  22. Garcia-Garayoa E, Blauenstein P, Bruehlmeier M, et al. Preclinical evaluation of a new, stabilized neurotensin (8–13) pseudopeptide radiolabeled with 99mTc. J Nucl Med. 2002;43:374–383
  23. Franz B, Florent B, Marek K, et al. Radiolabeled neurotensin analog, 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients. J Nucl Med. 2003;44:1649–1654
  24. Bruehlmeier M, Garayoa EG, Blanc A, et al. Stabilization of neurotensin analogues: effect on peptide catabolism, biodistribution and tumor binding. Nucl Med Biol. 2002;29:321–327
  25. Yumin Z, Yi W, Ning L, et al. In vitro investigations of tumor targeting with 99mTc-labeled antisense DNA. J Nucl Med. 2001;42:1660–1669
  26. Jason SL, Michael RL, Ananth S, et al. Comparison of four 64Cu-labeled somatostain analogues in vitro and in a tumor-bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy. J Med Chem. 1999;42:1341–1347
  27. Smith CJ, Sieckman GL, Owen NK, et al. Radiochemical investigations of [188Re(H2O)(CO)3-diaminopropionic acid-SSS-bombesin(7–14) NH2]: synthesis, radiolabeling and in vitro/in vivo GRP receptor targeting studies. Anticancer Res. 2003;23:63–70
  28. Pallela VR, Thakur ML, Chakder S, et al. 99mTc-labeled vasoactive intestinal peptide receptor agonist: functional studies. J Nucl Med. 1999;40:352–360
  29. Vincent JP, Mazella P, Kitabgi P, et al. Neurotensin and neurotensin receptors. Trends Pharmacol Sci. 1999;20:302–309
  30. Moody TW, Chiles J, Casibang M, et al. SR4892 is a neurotensin receptor antagonist which inhibits the growth of small cell lung cancer cells. Peptides. 2001;22:109–115
  31. Simon GR, Wangner H. Small cell lung cancer. Chest. 2003;123:259S–271S
  32. Pequeux C, Keegan BP, Hagelstein MT, et al. Oxytocin- and vasopressin-induced growth of human small cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr Ralat Cancer. 2004;11:871–885
  33. Garcia GE, Allemann-Tannahill L, Blauenstein P, et al. In vitro and in vivo evaluation of new neurotensin (8–13) analogues with high affinity for NT1 receptors. Nucl Med Biol. 2001;28:75–84
  34. Ohad M, Marc HB, Alain L, et al. Europium-labeled epidermal growth factor and neurotensin: novel probes for receptor-binding studies. Anal Biochem. 2002;301:75–81
  35. Schubiger PA, Allemann-Tannahill L, Eglia A, et al. Catabolism of neurotensins: implications for the design of radiolabeling strategies of peptides. Q J Nucl Med. 1999;43:155–158

PII: S0969-8051(06)00038-2

doi: 10.1016/j.nucmedbio.2006.03.003

Nuclear Medicine and Biology
Volume 33, Issue 4 , Pages 505-512 , May 2006

Article Tools

* Image Usage & Resolution